Ibex Medical Analytics Receives the US FDA’s 510(k) Clearance for Ibex Prostate Detect
Shots:
- The US FDA has granted 510(k) clearance to Ibex Prostate Detect, which generates heatmaps using AI to detect small & rare missed prostatic cancers
- In studies, the device showed 99.6% PPV for cancer heatmap accuracy & detected 13% rate of missed cancer in pts initially diagnosed as benign, where these false negatives were later confirmed by pathologists
- The device analyses scanned histopathology WSIs from H&E-stained, formalin-fixed, paraffin-embedded prostate core needle biopsies to identify missed tumors, plus provides case & slide-level alerts while also directing heatmap to cancer-containing areas. It also incl. solutions which are CE-IVD certified & are registered with the MHRA, TGA & ANVISA
Ref: Businesswire | Image: Ibex
Related News:- AliveDx Seeks US FDA’s 510(k) Clearance for MosaiQ AiPlex Multiplex Microarray
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
